logo

Acceleron Pharma, Inc (XLRN)



Trade XLRN now with
  Date
  Headline
5/22/2018 7:00:22 AM Acceleron Begins PULSAR Phase 2 Trial Of Sotatercept In Pulmonary Arterial Hypertension
5/1/2018 7:07:34 AM Acceleron Receives FDA Fast Track Designation For ACE-083 In Facioscapulohumeral Muscular Dystrophy
2/28/2018 7:56:52 AM RBC Capital Markets Is Increasing Acceleron Pharma, Inc (XLRN) FY18 Rev. Estimate To 40.97 M From 39.40 M
2/28/2018 7:48:47 AM RBC Capital Markets Is Cutting Acceleron Pharma, Inc (XLRN) FY18 Estimate To -2.83 From -2.73
1/8/2018 9:07:00 AM Acceleron Reports Preliminary Results From Part 1 Of ACE-083 Phase2 Trial In Patients With Facioscapulohumeral Dystrophy
11/15/2017 4:02:03 PM Acceleron Appoints Karen Smith To Its Board Of Directors
11/7/2017 7:20:10 AM Acceleron Pharma Posts Q3 Net Loss Was $25.5 Mln
9/20/2017 8:49:27 PM Acceleron Pharma Prices Underwritten Public Offering Of 5.41 Mln Shares At $37.00/shr
9/19/2017 4:23:33 PM Acceleron Announces Proposed Public Offering Of Common Stock
6/23/2017 2:33:05 AM Acceleron Provides Updated Results From Ongoing Phase 2 Study Of Luspatercept In Myelodysplastic Syndromes
6/1/2017 7:34:28 AM Celgene And Acceleron Complete Target Enrollment In MEDALIST; Expect Top-line Results From Phase 3 Studies In Mid-2018